250 related articles for article (PubMed ID: 36912538)
21. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
22. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
[TBL] [Abstract][Full Text] [Related]
23. Radical prostatectomy versus observation for localized prostate cancer.
Wilt TJ; Brawer MK; Jones KM; Barry MJ; Aronson WJ; Fox S; Gingrich JR; Wei JT; Gilhooly P; Grob BM; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Sharifi R; Blank W; Pandya P; Andriole GL; Culkin D; Wheeler T;
N Engl J Med; 2012 Jul; 367(3):203-13. PubMed ID: 22808955
[TBL] [Abstract][Full Text] [Related]
24. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.
Wilt TJ; Jones KM; Barry MJ; Andriole GL; Culkin D; Wheeler T; Aronson WJ; Brawer MK
N Engl J Med; 2017 Jul; 377(2):132-142. PubMed ID: 28700844
[TBL] [Abstract][Full Text] [Related]
25. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
26. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
27. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ; Tsai HT; Haque R; Ulcickas Yood M; Van Den Eeden SK; Cassidy-Bushrow AE; Zhou Y; Keating NL; Smith MR; Aaronson DS; Potosky AL
World J Urol; 2016 Dec; 34(12):1611-1619. PubMed ID: 27084777
[TBL] [Abstract][Full Text] [Related]
28. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
29. Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Wilt TJ; Ullman KE; Linskens EJ; MacDonald R; Brasure M; Ester E; Nelson VA; Saha J; Sultan S; Dahm P
J Urol; 2021 Apr; 205(4):967-976. PubMed ID: 33350857
[TBL] [Abstract][Full Text] [Related]
30. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
31. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cooperberg MR; Vickers AJ; Broering JM; Carroll PR
Cancer; 2010 Nov; 116(22):5226-34. PubMed ID: 20690197
[TBL] [Abstract][Full Text] [Related]
32. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Neal DE; Metcalfe C; Donovan JL; Lane JA; Davis M; Young GJ; Dutton SJ; Walsh EI; Martin RM; Peters TJ; Turner EL; Mason M; Bryant R; Bollina P; Catto J; Doherty A; Gillatt D; Gnanapragasam V; Holding P; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Altman DG; Hamdy FC;
Eur Urol; 2020 Mar; 77(3):320-330. PubMed ID: 31771797
[TBL] [Abstract][Full Text] [Related]
33. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
Bill-Axelson A; Holmberg L; Filén F; Ruutu M; Garmo H; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Adami HO; Johansson JE;
J Natl Cancer Inst; 2008 Aug; 100(16):1144-54. PubMed ID: 18695132
[TBL] [Abstract][Full Text] [Related]
35. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
36. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials.
King MT; Chen MH; Collette L; Neven A; Bolla M; D'Amico AV
JAMA Netw Open; 2021 May; 4(5):e2111092. PubMed ID: 33999161
[TBL] [Abstract][Full Text] [Related]
37. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
Nyame YA; Wilkins L; Greene DJ; Ganesan V; Dai C; Almassi N; Stephenson AJ; Gong M; Berglund R; Klein EA
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):617-623. PubMed ID: 30996285
[TBL] [Abstract][Full Text] [Related]
38. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
Thompson IM; Tangen CM; Paradelo J; Lucia MS; Miller G; Troyer D; Messing E; Forman J; Chin J; Swanson G; Canby-Hagino E; Crawford ED
JAMA; 2006 Nov; 296(19):2329-35. PubMed ID: 17105795
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
